Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy

Stopped early · Phase 1

Conditions studied: Pancreatic Carcinoma, Tumors That Express CA 19-9

In brief

Open label, nonrandomized, dose-escalation with cohort expansion study of MVT-5873/MVT-1075 in subjects with previously treated, Carbohydrate Antigen 19-9 (CA19-9) positive malignancies (e.g., pancreatic adenocarcinoma).

Key facts

Study ID

NCT03118349

Run by

BioNTech Research & Development, Inc.

People needed

4

Starts

2017-06-01

Expected to finish

2018-04-11

Last updated by the study team

2023-04-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed, informed consent
• Age 18 or more years
• Histologically or cytologically confirmed, previously treated, locally-advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) or other CA19-9 positive malignancies
• Prior treatment with (or intolerance to) at least one standard systemic regimen for the patient's respective tumor
• Evidence of tumor expression of CA19-9 based on immunohistochemistry performed on tumor samples or elevated serum levels (≥1.5 x upper limits of normal [ULN]) of CA19-9 considered secondary to tumor
• Evaluable or measurable disease based on RECIST 1.1
• Recovered from any prior treatment related toxicity to at least Grade 1 with exception of Grade 2 alopecia or other Grade 2 toxicity with prior approval of the Medical Monitor
• If previously exposed to irradiation, the combined prior and anticipated exposure for Cycle 1 is not expected to exceed organ exposure limits outlined in the study protocol
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, or Karnofsky performance status (KPS) of 100% to 80%
• Adequate hematologic, renal and hepatic laboratory parameters
• Willingness to participate in collection of pharmacokinetic samples
• Willingness to use adequate contraception throughout study and for a period of 3 months after last dose of MVT-5873 or MVT-1075 (whichever is later)

You may not qualify if…

• Brain metastases unless previously treated and well controlled for at least 3 months
• Any tumor mass greater than 10 cm in longest diameter
• Other known active cancer(s) likely to require treatment in the next two years
• Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
• Prior radiation therapy encompassing more than 25% of the skeleton or prior treatment with 89Strontium or 153Samarium
• Fewer than 28 days from prior anticancer therapy including chemotherapy, hormonal, investigational, and/or biological therapies and irradiation except for:
• Ongoing hormonal therapy administered for control of cancer (e.g., breast cancer, prostate cancer), which may be continued throughout the study
• MVT-5873 and MVT-2163 administered as part of a different protocol
• Major surgery other than diagnostic surgery within 28 days of Study Day 1
• History of anaphylactic reaction to human, or humanized, antibody
• Pregnant or currently breast-feeding
• Known to be positive for human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C
• Psychiatric illness/social situations that would interfere with compliance with study requirements
• Significant cardiovascular risk including, but not limited to, recent (within 4 weeks) coronary stenting or myocardial infarction within 6 months

Where it is running

• HonorHealth Research Institute — Scottsdale, Arizona, United States
• MSKCC — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.